Yet another hrt update (4 months estradiol and spiro + > 4 years of fin and min) (you should absolutely not take estradiol and spiro if you look manly and want to continue to look manly) Progress Pictures 9/26/2024
The conversation discusses hair loss treatments, including finasteride, minoxidil, estradiol, and spironolactone, with a focus on their effects on hair regrowth and gender transition. The original poster shares their personal experience with these treatments, emphasizing that estradiol and spironolactone should not be used by those who want to maintain a masculine appearance.
View this post in the Community →
Similar Community Posts Join
6 / 1000+ resultscommunity Well… I Did It. Estrogen Saved My Hairline
OP transitioned and used Spironolactone, Estradiol Valerate, Minoxidil, and dermarolling, resulting in significant hair regrowth. They advise this method may not be suitable for cis men.
community 2 months of difference with estradiol and spiro (4 months total w/ estradiol & spiro; 4 years of minoxidil and finasteride) (you should not take estradiol or spiro if you look manly and want to continue looking manly)
Hair regrowth using estradiol, spironolactone, minoxidil, and finasteride, showing significant improvement over four years. HRT is not advised for cis men solely for hair loss due to feminizing effects.
community 4 years; fin 1mg/day @ 4 years; minox twice daily @ 3 years; estradiol 5mg/day @ 3 months; spiro 100 mg /day @ 3 months (Wet hair because it's easy to hide issues with dry hair)
The user shared their 4-year hair regrowth progress using finasteride, minoxidil, estradiol, and spironolactone. They noted significant regrowth by the second year and additional benefits from estradiol and spironolactone.
community Don't fall for the fear mongering bros
Hair loss treatments discussed include finasteride, minoxidil, spironolactone, and estradiol, with concerns about side effects like sexual dysfunction and feminization. Some users prefer hair transplants or shaving over medication due to potential side effects.
community 10 months of minoxidil + cheating
A user shared their positive experience with hair regrowth using minoxidil, hormone replacement therapy, and cyproterone acetate during their male-to-female transition. Another user discussed their successful hair transplant after transitioning and using finasteride, highlighting the challenges of hair loss and regrowth during transition.
community So we’re just ok with taking a research chemical now?
The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.
Related Research
6 / 1000+ results
research Androgenetic Alopecia: An Update Of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
research Hair Regrowth in a Male Patient with Extensive Androgenetic Alopecia on Estrogen Therapy
Estrogen therapy helped regrow hair in a bald man.
research Female Pattern Alopecia: Current Perspectives
Female pattern hair loss is caused by multiple factors and while treatments like topical minoxidil, hormone therapy, and low-level light therapy can help, none can fully cure it.
research The Hormonal Background of Hair Loss in Non-Scarring Alopecias
Hormones like androgens, estrogen, thyroid hormones, and stress hormones can contribute to hair loss, and treatments target these hormonal imbalances.
research Female Pattern Hair Loss: A Clinical, Pathophysiologic, and Therapeutic Review
No cure for female pattern hair loss, but various effective treatments exist.
research Hair: What Is New in Diagnosis and Management?
Female pattern hair loss diagnosed by scalp appearance, treated with combined therapies and targeted approaches.